<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; CRO</title>
	<atom:link href="http://www.tapanray.in/tag/cro/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>“Make Global Pharma Responsible in Homeland for Objectionable Conduct in Clinical Trials Elsewhere”</title>
		<link>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere</link>
		<comments>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/#comments</comments>
		<pubDate>Wed, 12 Feb 2014 01:30:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Azad]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Desiraju]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[Ghulam]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[keshav]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Nabi]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[objectionable]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4988</guid>
		<description><![CDATA[In the context of his recent meeting with Commissioner Margaret A. Hamburg of US-FDA, the Drug Controller General of India (DCGI) reportedly expressed his concern to ‘The Economic Times’ on the ‘objectionable conduct’ of global pharma in new drug trials &#8230; <a href="http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Clinical Trial Regime Deserves Support, Sans Threats</title>
		<link>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-clinical-trial-regime-deserves-support-sans-threats</link>
		<comments>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/#comments</comments>
		<pubDate>Thu, 30 Jan 2014 11:19:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[catalytic]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[threats]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4943</guid>
		<description><![CDATA[Recent Supreme Court intervention compelling the Union Government to enforce stringent regulations both for approval and conduct of Clinical Trials (CT) in India, has unfortunately met with some strong resistance with stronger words. Some of these voices are from credible &#8230; <a href="http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New ‘Patient Compensation’ Norms on Clinical Trials in India: Overdue Action, Sharp Reaction and Ethical Issues</title>
		<link>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues</link>
		<comments>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/#comments</comments>
		<pubDate>Mon, 25 Feb 2013 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[controlled]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[GSR]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[negligence]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[overdue]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reaction]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1996</guid>
		<description><![CDATA[Responding to the damning stricture made by the Supreme Court on January 3, 2013, the Ministry of Health, as expected, by a gazette notification of January 30, 2013 has made the norms of compensation to patients participating in Clinical Trials &#8230; <a href="http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
